Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
To accelerate the development of next-generation radioconjugates to treat cancer
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Targeting deadly drug-resistant acinetobacter infections
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
